Helsinn has announced new plans to create a competitive organization focused on manufacturing highly potent compounds with a remarkable capacity for R & D and production. Both investments and manufacturing facilities of the new organization of Ireland and Switzerland are part of this strategy.
In March this year, Helsinn made an investment of around EUR 13 million, receiving support from the Government of Ireland through the IDA (Irish Development Authority) to build a center of excellence in the field of research and development of oral solid dosage (OSD), creating 10 positions for high-value research in one of its facilities near Dublin (Ireland). Now, Helsinn Chemicals in Biasca Organization (Switzerland), after an initial investment of 5 million euros completed in recent years, aims to expand its services in developing and manufacturing facilities in Switzerland Helsinn Advanced Synthesis.
As part of the plan also emphasizes the sale of the plant Helsinn Mulhuddart Chemicals Ireland Ltd. (Dublin, Ireland) to the Italian company Medinco CFM Group, a pharmaceutical chemical company based in Milan (Italy) and specializes in supply of generic active pharmaceutical ingredients for its global customer base. Today announced the signing of the agreement between the parties.